Campath (Genzyme Corporation)
Welcome to the PulseAid listing for the Campath drug offered from Genzyme Corporation. This CD52-directed Antibody Interactions [MoA],CD52-directed Cytolytic Antibody [EPC] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: | Genzyme Corporation |
NON-PROPRIETARY NAME: | ALEMTUZUMAB |
SUBSTANCE NAME: | ALEMTUZUMAB |
TYPE: | HUMAN PRESCRIPTION DRUG |
PHARMA CLASS: | CD52-directed Antibody Interactions [MoA],CD52-directed Cytolytic Antibody [EPC] |
ROUTE: | INTRAVENOUS |
DOSAGE FORM: | INJECTION |
MARKETING CATEGORY NAME: | BLA |
START MARKETING DATE: | 2009-11-30 |
END MARKETING DATE: | 0000-00-00 |
Campath HUMAN PRESCRIPTION DRUG Details:
Item Description | Campath from Genzyme Corporation |
LABELER NAME: | Genzyme Corporation |
DEA SCHEDULE: |
|
ACTIVE STRENGTH: | 30(mg/mL) |
START MARKETING DATE: | 2009-11-30 |
END MARKETING DATE: | 0000-00-00 |
PRODUCT ID: | 58468-0357_d986d7b0-b2f5-48d7-af39-f01669bc674f |
PRODUCT NDC: | 58468-0357 |
APPLICATION NUMBER: | BLA103948 |
Other ALEMTUZUMAB Pharmaceutical Manufacturers / Labelers: